← Back to Search

Imaging

MRI-Guided Biopsy Selection for Prostate Cancer (MAST Trial)

N/A

Waitlist Available

Led By Sanoj Punnen, MD, MAS

Research Sponsored by University of Miami

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 35 and ≤ 85 years

Patients must agree to undergo serial multiparametric MRI and MRI-guided biopsy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 36 months

Awards & highlights

MAST Trial Summary

This trial is testing whether MRI, along with a targeted biopsy of any suspicious lesions, can help detect which patients are more likely to need treatment sooner.

Who is the study for?

Men aged 35-85 with confirmed prostate cancer within the last 18 months, a PSA level ≤20 ng/ml, and who have had at least an 8-core biopsy. Participants must be able to undergo MRI scans with contrast and agree to regular MRI-guided biopsies and quality of life questionnaires. Exclusions include high-grade cancers, prior significant prostate treatments or surgeries (except certain benign procedures), renal insufficiency preventing MRI use, bilateral hip replacements, or other active malignancies.Check my eligibility

What is being tested?

The trial is testing whether using Magnetic Resonance Imaging (MRI) along with targeted biopsies can help identify patients who need earlier treatment for prostate cancer. It involves serial multiparametric MRIs and guided biopsies based on suspicious findings in the images.See study design

What are the potential side effects?

Potential side effects from this trial may include discomfort or pain during the MRI-guided biopsy procedure, risks associated with contrast agents used in MRIs such as allergic reactions or kidney problems in susceptible individuals.

MAST Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 35 and 85 years old.

Select...

I agree to have multiple MRI scans and MRI-guided biopsies.

MAST Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of Disease Progression within the first two surveillance biopsies

Secondary outcome measures

Area under Receiver Operating Characteristic (ROC) curve

Health-Related Quality of Life Scores: EPIC SF-12

Health-Related Quality of Life Scores: MAX-PC

+1 more

MAST Trial Design

1Treatment groups

Experimental Treatment

Group I: Active SurveillanceExperimental Treatment2 Interventions

Participants in this group will receive a Multi-Parametric Magnetic Resonance Imaging (MP-MRI) of the prostate/pelvis and MRI-guided prostate biopsy at baseline (0-3 months from enrollment) and at the 12th, 24th and 36th month follow up.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MRI-Guided Biopsy

2006

N/A

~90

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of MiamiLead Sponsor

899 Previous Clinical Trials

409,475 Total Patients Enrolled

16 Trials studying Prostate Cancer

3,680 Patients Enrolled for Prostate Cancer

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,952,332 Total Patients Enrolled

28 Trials studying Prostate Cancer

6,750 Patients Enrolled for Prostate Cancer

National Cancer Institute (NCI)NIH

13,658 Previous Clinical Trials

40,924,280 Total Patients Enrolled

560 Trials studying Prostate Cancer

506,906 Patients Enrolled for Prostate Cancer

Media Library

MRI-Guided Biopsy (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT02242773 — N/A

Prostate Cancer Research Study Groups: Active Surveillance

Prostate Cancer Clinical Trial 2023: MRI-Guided Biopsy Highlights & Side Effects. Trial Name: NCT02242773 — N/A

MRI-Guided Biopsy (Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02242773 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor seeking participants who are over forty years of age?

"This clinical experiment accepts participants aged 35 to 85. For those below 18, there are 76 trials available and a total of 1316 studies for people older than 65 years old."

Answered by AI

Would I be eligible to join this clinical experiment?

"This medical study is searching for 207 individuals with prostate cancer between the ages of 35 and 85. To be considered, applicants must satisfy these requirements: Age ≥ 35 years and ≤ 85 years old;"

Answered by AI

Does this research project currently have any openings for volunteers?

"Data from clinicaltrials.gov denotes that this trial is not taking in participants at present, despite its initial posting on November 12th 2014 and subsequent update on September 14th 2022. However, there are currently 1322 other medical studies for which researchers seek volunteers."

Answered by AI

Recent research and studies

formation/NLM/NIH, NCBI. “Gprobe”. 2017. Web. <https://github.com/ncbi/gprobe>..Journal

Gprobe

Information/NLM/NIH, NCBI. 2017. “Gprobe”. GitHub repository. https://github.com/ncbi/gprobe.

clinicaltrials.govStudy

MRI Based Active Selection for Treatment Trial

Sanoj Punnen, MD, MAS 2014. "MRI Based Active Selection for Treatment Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02242773.